The Association between Parasitemia and Liver Enzyme Alterations in Malaria Patients: ABO Blood Group as A Non-Contributory Factor Authors: Selva Aminizadeh, Elham Shokri, Mehdi Mohebali, Haleh Hanifian, Salman Zafari, Mahdi Edalati, Saeed Bahadory, Hossein Hosseinifard, Mehdi Nateghpoor Published: 2025 ABSTRACT AbstractBackground:Malaria, a life-threatening parasitic disease, exhibits diverse clinical manifestations influenced by parasite species, host immunity, and treatment access. Emerging evidence suggests that individual biological factors, such as ABO blood group and liver enzyme status, may also affect disease severity. This study investigates the relationship between blood type, liver enzyme levels, and malaria severity in affected patients.Methods:A case-control study was conducted on malaria patients at the National Malaria Laboratory, Tehran University of Medical Sciences, from May 2022 to October 2024. Blood samples were analyzed for ABO blood grouping and liver enzymes: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP). Malaria severity was classified according to WHO criteria. Statistical analyses, including chi-square tests and logistic regression, evaluated associations between blood group, liver enzyme levels and disease severity.Results:A total of 100 participants were included: 50 malaria-positive patients and 50 healthy controls, with a mean age of 38.10±16.40 years. Malaria patients showed significantly higher AST, ALT and ALP levels compared to controls (p= 0.001). No significant association was found between ABO blood group and liver enzyme levels in either group (p> 0.05). Liver enzyme levels correlated significantly with parasitemia (p< 0.001), with higher parasite loads linked to greater hepatic dysfunction.Conclusion:This study highlights the significant impact of parasitemia levels on liver function in malaria patients, while the ABO blood group appeared unrelated to liver enzyme alterations. Liver enzyme profiles may serve as valuable biomarkers for assessing malaria severity and guiding clinical management.Keywords: Malaria, Blood groups, Liver enzyme, Disease severity, Human Introduction Despite significant global efforts to prevent and treat malaria, the disease remains a major public health threat, with an estimated 282 million cases and 610,000 deaths reported in 2024 across 80 countries (1). Although both preventable and treatable, malaria continues to impact millions, particularly in endemic regions. In Iran, the disease persists in the southern and southeastern provinces of Sistan and Baluchestan and Hormozgan, where over 80% of the country’s malaria cases are documented (2). Malaria in humans is caused by five Plasmodium species, P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi, transmitted by the bite of infected female Anopheles mosquitoes (3, 4). Following transmission, sporozoites are injected into the skin during the mosquito’s blood meal, where they may persist for 1–3 hours before potentially being cleared by the lymphatic system, initiating an immune response. Surviving sporozoites enter the bloodstream, rapidly migrating to the liver, where they infect hepatocytes and transform into exoerythrocytic forms over 2–10 days. This process results in the release of up to 40,000 merozoites into the bloodstream via merosomes. Although the liver stage is clinically silent, it represents a crucial focus for research as it precedes the symptomatic blood-stage infection and progression to severe disease (5–8). Jaundice and liver dysfunction are common clinical features in severe malaria cases (9, 10). Histopathological examination of affected liver tissue typically reveals hepatocyte necrosis, granulomatous lesions, Kupffer cell hyperplasia, malarial pigment deposition, bile flow obstruction and monocyte infiltration within malarial nodules. These pathological changes contribute to an increased risk of liver failure and systemic complications in severe malaria (9, 11–13). Although clinical malaria is frequently associated with liver abnormalities, comprehensive knowledge about its broader clinical aspects remains limited. In most of the literature, malaria-related liver dysfunction is primarily characterized by abnormal laboratory values, particularly elevated levels of bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (13–16). Damage to hepatocytes leads to the leakage of intracellular enzymes such as AST, ALT and alkaline phosphatase (ALP) into the bloodstream, resulting in elevated serum levels of these enzymes in malaria patients (4). Monitoring changes in these biomarkers between the acute and convalescent phases may aid in evaluating disease progression and the early response to treatment (17, 18). Additionally, variations in the physicochemical properties of Plasmodium-infected blood appear to depend on factors such as malaria endemicity, nutritional status, demographic characteristics and individual immune responses (19). The ABO blood group system is genetically determined and varies across populations and ethnic groups (20). These carbohydrate-based antigens are present on red blood cells and various tissues, influencing protein function and cell-to-cell interactions, especially during infections. In malaria, parasite adhesion to host cells contributes to disease severity and these interactions may differ based on blood group (21, 22). Beyond host physiological responses, genetic factors such as the ABO blood group may also influence disease occurrence. Some experimental and epidemiological studies have shown differences in the propensity of Anopheles mosquitoes to feed on ABO blood groups, as well as the incidence of malaria in different blood groups (23, 24). Therefore, this study aimed to investigate the potential association between ABO blood group, liver function test abnormalities, and parasite levels in patients with P. falciparum, P. vivax, and mixed-species infections in an endemic region of Iran. Materials and Methods Study design and participants A case-control study was conducted at the National Malaria Laboratory, Tehran University of Medical Sciences, from May 2022 to October 2024. A total of 100 participants were enrolled, including 50 malaria-positive patients and 50 healthy controls. The control group in this study consisted of individuals selected from the same source population as the case group and matched in age, sex and geographic region. Malaria infection was confirmed negative using peripheral blood smear and rapid diagnostic test (RDT). Exclusion criteria included individuals with a history of chronic liver disease, hepatitis B surface antigen (HBs Ag) or hepatitis C virus antigen (HCV Ag) positivity, and other known infectious or non-infectious causes of liver dysfunction. Sample collection and laboratory analysis Blood samples were collected from all participants using standard phlebotomy techniques. ABO blood grouping was performed using both the cell grouping (forward type) and serum grouping (reverse type) methods to ensure accuracy and consistency. Liver function tests (LFTs), e.g., aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), were measured using routine automated biochemistry analyzers based on standard enzymatic colorimetric methods using the Delta Darman Part kit (Tehran, Iran). To exclude other causes of liver dysfunction, all participants were screened for hepatitis B surface antigen (HBs Ag) and hepatitis C virus antigen (HCV Ag) using the Wantai kit (Beijing, China) according to the manufacturer’s instructions. Parasitemia and species identification Malaria diagnosis was confirmed by examining both thin and thick peripheral blood smears, prepared from capillary blood samples. Smears were stained with 10% Giemsa solution for 20 minutes, then examined under a light microscope. Parasite species identification (P. falciparum, P. vivax, or mixed infections) was performed on thin smears, while parasitemia levels were calculated from thick smears by counting the number of asexual parasites per 200 white blood cells (WBCs) and converting the result to parasites per microliter of blood, assuming a standard WBC count of 8,000/μL. Parasitemia was categorized as few (1 to 999 parasites per micro-liter), moderate++ (1000 to 9999 parasites per microliter), or many+++ (over 10,000 parasites per microliter) (25). Classification of malaria severity Malaria severity was classified according to the World Health Organization (WHO) criteria. Severe malaria was defined by the presence of one or more of the following features: impaired consciousness or coma (cerebral malaria), severe anemia (hemoglobin <5 g/dL), hyperparasitemia (parasite density ≥100,000 parasites/μL), jaundice accompanied by evidence of organ dysfunction, respiratory distress, or signs of vital organ failure. Patients who did not meet these criteria were classified as having uncomplicated malaria. Statistical analyses The results were reported in the form of descriptive statistics as mean (standard deviation) for quantitative variables and number (percentage) for qualitative variables. In order to compare the frequency distribution of gender and blood group between the two diseased and healthy groups, the Chi-square test was used. The variables of origin, parasitemia, and parasite species were measured only in the diseased group; only the frequency of these variables in the diseased group was reported. In order to compare liver enzymes between the two groups, the independent t-test was used. A probability value (p-value) less than 5 percent was considered a significant level and R software version 4.4.2 was used to analyze the data. Results Participant demographics A total of 100 participants were enrolled in the study, comprising 50 malaria-positive patients and 50 healthy controls. Among the total participants, 21 were female and 79 were male. The age range was between 12 and 72 years, with a mean age of 38.10±16.40 years. There was a statistically significant difference in gender distribution between the patient and control groups (p= 0.007), with females representing 10% of the patient group and 32% of the control group. The nationality distribution among malaria patients was heterogeneous, including 44% Iranian, 34% Afghan, 4% Indian, 4% Pakistani and 2% each from Cameroon, Sierra Leone, Sudan and Kenya/Somalia. All healthy controls were Iranian nationals (Table 1). Table 1.Demographic characteristics of study participants Groups p-value Patient n (%) Healthy n (%) Total n (%) Gender Female5 (10)16 (32)21 (21)0.007Male45 (90)34 (68)79 (79) Origin Iran22 (44)50 (100)72 (72)-Afghanistan17 (34)-17 (17)India2 (4)-2 (2)Kameron1 (2)-1 (1)Kenya and Somalia1 (2)-1 (1)Pakistan2 (4)-2 (2)Sierra Leone1 (2)-1 (1)Sudan1 (2)-1 (1)NA3 (6)-3 (3) Parasitemia Few5 (10)-5 (10)-Many11 (22)-11 (22)Moderate34 (68)-34 (68) Parasite species P. f 12 (24)-12 (24)- P. v 38 (76)-38 (76)NA: Not stated, n: number, P. f: Plasmodium falciparum, P. v: Plasmodium vivax Demographic characteristics of study participants NA: Not stated, n: number, P. f: Plasmodium falciparum, P. v: Plasmodium vivax Parasitemia levels and parasite species In this study, parasitemia levels among the malaria-positive patients were categorized into three distinct groups based on the density of parasites observed in peripheral blood smears. Approximately 10% of the patients had a low parasite density (few), indicating a mild level of infection. The majority of patients, 68%, exhibited a moderate parasitemia, reflecting a more substantial burden of parasites circulating in the bloodstream. Lastly, 22% of the patients were classified as having a high parasite density (many), which is often associated with more severe clinical manifestations and a greater risk of complications. Regarding the species distribution of the malaria parasites, the vast majority of infections were caused by P. vivax, accounting for 76% of the cases. In contrast, infections due to P. falciparum represented 24% of the total malaria cases (Fig. 1). This species distribution aligns with regional epidemiological patterns observed in Iran and neighboring endemic areas, where P. vivax is the predominant malaria species, but P. falciparum remains a significant cause of morbidity due to its higher pathogenicity. Distribution of Plasmodium species (Plasmodium falciparum, P. vivax) and parasitemia levels (few, moderate, and many) among malaria patients Liver enzyme levels and blood group The mean levels of liver enzymes-AST, ALT and ALP-were significantly elevated in malaria patients compared to healthy controls (p< 0.001 for all enzymes). Specifically, among patients, mean AST levels varied by blood group, ranging from 96.24±34.49 IU/L in group AB to 158.81±76.98 IU/L in group B, whereas controls exhibited consistently low AST levels of 30.93±9.04 to 31.37±7.83 IU/L across blood groups. Similar patterns were observed for ALT and ALP, with malaria patients showing markedly higher enzyme levels than controls, regardless of blood group (Table 2). Table 2.Liver enzyme (AST, ALT and ALP) levels (Mean±SD) by ABO blood group in malaria patients and healthy controls Enzyme ABO Patients n Mean±SD (IU/L) Controls n Mean±SD (IU/L) p-value (group) p-value (blood group)* AST A17123.47±42.821131.37±7.83<0.0010.027AB696.24±34.49631.25±6.19B16158.81±76.981330.93±9.04O11138.79±48.922031.14±8.22 ALT A17109.62±39.491125.32±9.27<0.0010.033AB687.78±33.11630.94±6.08B16139.20±69.371331.08±9.69O11118.76±42.232024.99±8.20 ALP A17448.88±134.3611226.91±87.00<0.0010.039AB6417.67±114.186236.67±65.45B16570.19±188.7413234.23±65.13O11500.18±118.8820237.60±51.86n: number, AST: aspartate aminotransferase, ALT: alanine aminotransferase and ALP: alkaline phosphatase,*: The reported p-values are for the General linear model (GLM) Liver enzyme (AST, ALT and ALP) levels (Mean±SD) by ABO blood group in malaria patients and healthy controls n: number, AST: aspartate aminotransferase, ALT: alanine aminotransferase and ALP: alkaline phosphatase, : The reported p-values are for the General linear model (GLM) Based on Table 3, it can be seen that with blood group, gender and age remaining constant, the average AST in the patient group was 104.71 units lower than the healthy group, which was statistically significant (p< 0.001). Also, the average ALT in the patient group was 90.53 units lower than the healthy group, which was also statistically significant (p< 0.001) and the average ALP in the patient group was 265.35 units lower than the healthy group, which was also statistically significant (p< 0.001). Table 3.Estimated regression coefficients based on the General Linear Model (GLM) Variables B Std. Error t-value p-value 95% Confidence Interval AST Intercept16.95515.2431.1120.269(−13.31; 47.23)HealthyRefPatient−104.7099.186−11.398<0.001( −122.95; −86.47)ORefA−9.17810.632−0.8630.390(−30.29; 11.94)AB−20.41013.689−1.4910.139(−47.59; 6.77)B17.27710.6461.6230.108(−3.86; 38.42)FemaleRefMale19.13010.9111.7530.083(−2.54; 40.8)Age0.4650.2711.7160.090(−0.07; 1) ALT Intercept15.81813.8031.1460.255(−11.59; 43.23)HealthyRefPatient−90.5388.319−10.884<0.001(−107.06; −74.02)ORefA−5.5269.628−0.5740.567(−24.65; 13.59)AB−11.57712.396−0.9340.353(−36.19; 13.04)B19.2909.6412.0010.048(0.15; 38.43)FemaleRefMale17.1479.8801.7360.086(− 2.47; 36.77)Age0.3350.2461.3650.176(−0.15; 0.82) ALP Intercept205.53644.3614.633<0.001(117.44; 293.63)HealthyRefPatient−265.35826.734−9.926<0.001(−318.45; −212.27)ORefA−36.90730.943−1.1930.236(−98.35; 24.54)AB−41.61139.838−1.0440.299(−120.72; 37.5)B47.29330.9831.5260.130(−14.23; 108.82)FemaleRefMale33.50931.7531.0550.294(− 29.55; 96.56)Age0.9230.7891.1700.245(−0.64; 2.49) Estimated regression coefficients based on the General Linear Model (GLM) Table 4 shows the results of multivariate regression to investigate the relationship between blood group and liver enzyme levels. According to Table 4, it is observed that the effect of parasitemia and gender on AST level was significant, but the effect of age on AST was not significant. On average, the AST level in patients with blood groups A and AB was 12.51 and 13.02 units lower than in patients with blood group O, respectively, but was 19.56 units higher in patients with blood group B. These values were not statistically significant. Table 4.Multivariate regression coefficients for examining the relationship between blood type and liver enzyme levels Liver enzyme levels Variables Unstandardized Coefficients Std. Error Standardized Coefficients t-value p-value AST Intercept−23.6619.80−1.190.235Blood GroupORefA−12.5110.02−0.08−1.250.215AB−13.0213.01−0.06−1.000.320B19.5610.020.131.950.054ParasitemiaFewRefModerate137.7112.460.6711.05<0.001Many90.009.510.669.46<0.001GenderFemaleRefMale25.2310.380.152.430.017Age0.270.260.071.030.307 ALT Intercept−20.4118.17−1.120.264Blood GroupORefA−8.269.20−0.06−0.900.371AB−5.5111.93−0.03−0.460.645B21.179.190.162.300.023ParasitemiaFewRefModerate117.6211.430.6510.29<0.001Many78.478.720.658.99<0.001GenderFemaleRefMale22.159.520.152.330.022Age0.170.240.050.720.472 ALP Intercept133.5559.592.240.027Blood GroupORefA−43.9630.17−0.11−1.460.148AB−25.9839.15−0.05−0.660.509B52.1330.140.131.730.087ParasitemiaFewRefModerate335.1637.490.628.94<0.001Many234.2528.620.658.19<0.001GenderFemaleRefMale46.4031.230.111.490.141Age0.500.780.050.640.521 Multivariate regression coefficients for examining the relationship between blood type and liver enzyme levels Statistical analysis revealed no significant effect of ABO blood group on liver enzyme levels within either the patient or control groups (p-values: AST=0.027, ALT=0.033, ALP=0.039), indicating that the observed liver enzyme elevations are primarily associated with malaria infection rather than blood group differences (Fig. 2). The effect of ABO blood group on liver enzyme levels (AST, ALT and ALP) Liver enzyme levels and parasitemia Liver enzyme levels varied significantly according to parasitemia intensity (p< 0.001 for AST, ALT and ALP). Patients with many parasites demonstrated the highest mean enzyme levels (AST: 196.34±65.15 IU/L; ALT: 174.45±57.48 IU/L; ALP: 633.73±168.04 IU/L), followed by those with moderate parasitemia and the lowest levels were observed in patients with few parasites (AST: 74.55±28.55 IU/L; ALT: 62.91±24.30 IU/L; ALP: 324.20±54.55 IU/L) (Table 5). These findings suggest a positive correlation between parasite density and hepatic dysfunction. Table 5.Liver enzyme (AST, ALT and ALP) levels (Mean ± SD) by parasitemia intensity in malaria patients Enzyme Parasitemia level Mean ± SD (IU/L) p-value AST Few74.55 ± 28.55Moderate123.87 ± 42.29<0.001Many196.34 ± 65.15 ALT Few62.91 ± 24.30Moderate108.54 ± 37.19<0.001Many174.45 ± 57.48 ALP Few324.20 ± 54.55Moderate475. 59 ± 126.47<0.001Many633.73 ± 168.04AST: aspartate aminotransferase, ALT: alanine aminotransferase and ALP: alkaline phosphatase Liver enzyme (AST, ALT and ALP) levels (Mean ± SD) by parasitemia intensity in malaria patients AST: aspartate aminotransferase, ALT: alanine aminotransferase and ALP: alkaline phosphatase Table 6 shows the results of post hoc tests using Tukey's method for pairwise comparison of groups. According to the results, it can be seen that the difference in mean liver enzyme levels between each pair of parasitemia levels was statistically significant. Table 6.Post hoc test results for pairwise comparisons between parasitemia levels Dependent Variable Group Mean Difference (I–J) Std. Error 95% CI for Mean Difference p-value I J AST FewMany−121.7925.46(−173.01; −70.57)<0.001Moderate−49.3322.61(−94.81; −3.84)0.034ManyModerate72.4716.37(39.52; 105.41)<0.001 ALT FewMany−111.5422.40(−156.6; −66.48)<0.001Moderate−45.6319.89(−85.64;−5.62)0.026ManyModerate65.9114.40(36.93; 94.89)<0.001 ALP FewMany− 309.5371.33(−453.03; −166.02)<0.001Moderate−151.3963.35(−278.83;−23.95)0.021ManyModerate158.1445.88(65.85; 250.43)0.001 Post hoc test results for pairwise comparisons between parasitemia levels Table 7 shows the results of the regression model to compare the levels of liver enzymes between the two species, controlling for gender and age in the patients. Based on the results, it is observed that the mean levels of liver enzymes AST, ALT and ALP in patients with P. vivax were 42.70, 34.17 and 54.78 units lower than in patients with P. falciparum, respectively. These values were statistically significant for AST and ALT (p< 0.05) but not for ALP (p> 0.05). Table 7.Results of the regression model to compare liver enzyme levels between Plasmodium falciparum and P. vivax, controlling for gender and age in patients Unstandardized Coefficients Std. Error Standardized Coefficients t-value p-value AST Intercept118.71271.0231.6710.101Parasite species P. falciparum Ref P. vivax −42.70318.354−0.314−2.3270.024GenderFemaleRefMale55.00425.1870.2842.1840.034Age0.9060.5930.2041.5260.134 ALT Intercept91.97164.4011.4280.160Parasite species P. falciparum Ref P. vivax −34.17316.643−0.282−2.0530.046GenderFemaleRefMale50.84522.8390.2942.2260.031Age0.7430.5380.1881.3810.174 ALP Intercept459.271200.4842.2910.027Parasite species P. falciparum Ref P. vivax −78.54851.810−0.217−1.5160.136GenderFemaleRefMale90.35671.0990.1761.2710.210Age2.4871.6750.2111.4850.144 Results of the regression model to compare liver enzyme levels between Plasmodium falciparum and P. vivax, controlling for gender and age in patients Spearman's rank correlation was calculated between parasitemia and liver enzyme levels. The correlation coefficient between parasitemia and liver enzyme levels of AST, ALT and ALP was found to be 0.58, 0.60 and 0.55, respectively, which were statistically significant (p< 0.001). Discussion The present study provides compelling evidence of significant hepatic involvement in malaria patients, demonstrated by marked elevations in serum AST, ALT and ALP levels compared to healthy controls. These findings confirm the hepatic tropism of Plasmodium species during the erythrocytic stage and underscore the importance of routine liver function monitoring in malaria management, particularly in endemic regions like Iran, where P. vivax predominates (2). Importantly, the significant liver injury observed in our predominantly P. vivax cohort, which included both Iranian and non-Iranian nationals, adds population-specific evidence to the growing body of literature challenging the traditional view of P. vivax malaria as a benign infection. This demographic heterogeneity reflects the current epidemiology of malaria in Iran and underscores that the capacity of P. vivax to induce clinically relevant hepatic dysfunction is not restricted to a particular nationality or host background. Our findings therefore support the concept that hepatic complications are a fundamental component of malaria pathophysiology in P. vivax infections, rather than an exception limited to P. falciparum. These findings are particularly relevant for regions such as Iran, where P. vivax predominates and is often under-recognized as a cause of severe systemic involvement (9, 10, 26). These results mirror findings from Kochar et al. (13) and Jain et al. (9), both of whom demonstrated hepatic dysfunction even in P. vivax infections previously considered benign. This paradigm shift is critical for clinicians and public health policymakers in P. vivax-endemic areas. The significant liver injury observed in our predominantly P. vivax cohort, which included both Iranian and non-Iranian nationals, adds to the growing body of evidence challenging the traditional benign classification of this species. This reinforces that hepatic complications are a core feature of malaria pathophysiology, not an exception reserved for P. falciparum. Our study reveals a strong, positive and statistically significant correlation between parasitemia intensity and the degree of liver enzyme derangement. Patients with high parasitemia exhibited enzyme levels more than threefold greater than those with low parasite densities, a pattern also reported by Kochar et al. (13) and Abro et al. (16). These findings highlight parasitemia as not merely a diagnostic parameter but a reliable prognostic marker of hepatic involvement, which should be closely monitored to pre-empt complications such as malarial hepatitis, cholestasis, or even acute liver failure (12–14). Interestingly, no significant association was observed between ABO blood group and liver enzyme alterations in either malaria patients or healthy controls. While ABO blood group antigens have been implicated in malaria pathogenesis through mechanisms such as rosetting, cytoadherence and modulation of parasitemia thresholds, our findings suggest that these effects may not extend to hepatic involvement (20, 21). This implies that malaria-associated liver dysfunction is more directly driven by parasite burden and host inflammatory responses than by erythrocyte surface antigens. In other words, although the ABO blood group may influence susceptibility to infection or certain hematological complications, it does not appear to play a determining role in malaria-induced hepatopathy. This distinction is clinically relevant, as it supports the use of liver enzyme abnormalities as universal severity markers across blood groups, without the need for blood group-specific risk stratification. Our findings align with Gupte et al. (20) and Amodu et al. (22), indicating that ABO antigens may not influence hepatic involvement directly, even if they modulate other clinical outcomes like anemia or parasitemia thresholds. This distinction clarifies the need for further focused research on the immunogenetic determinants of malarial hepatopathy beyond ABO grouping. The observed distribution of parasite species, predominantly P. vivax (76%) with a smaller proportion of P. falciparum (24%), aligns with regional malaria epidemiology in southern Iran (2). However, the substantial hepatic involvement in P. vivax cases underscores the evolving clinical profile of this species. Growing international evidence suggests that P. vivax malaria, particularly in Southeast Asia and the Eastern Mediterranean region, is increasingly associated with severe hepatic complications (10, 11, 13, 26), likely driven by parasite genetic shifts, host factors and regional treatment delays. This study’s strengths include its prospective, controlled design, standardized parasitological and biochemical assessments and strict exclusion of confounding hepatopathies such as viral hepatitis through ELISA screening. Nevertheless, certain limitations merit acknowledgment. The modest sample size, particularly within blood group and parasite species subgroups, may limit the generalizability of the null association findings and constrain statistical power for stratified analyses. Additionally, the cross-sectional design limits assessment of dynamic changes in liver enzymes during treatment and convalescence. Longitudinal studies are necessary to elucidate recovery patterns, relapse risk in P. vivax and the long-term hepatic sequelae of malaria infections. Clinically, these findings reinforce the necessity for comprehensive liver function monitoring in malaria patients, particularly those with high parasitemia. Elevated AST, ALT and ALP levels are valuable markers for anticipating complications and should inform management decisions such as hospitalization, adjunctive therapies and hepatic protective strategies. In addition, future studies with a larger sample size are recommended to make the results more accurate. Furthermore, the demographic differences between our patient and control groups, particularly in gender and nationality, though reflective of the local malaria burden, may introduce confounding. Future studies with matched controls would help isolate the specific effects of malaria infection. Conclusion This study contributes novel regional data on the relationship between malaria, parasitemia and hepatic dysfunction in Iran, supporting global evidence that P. vivax can no longer be considered a purely benign infection. Future multicenter, longitudinal and molecular studies should aim to delineate the precise pathophysiological mechanisms of hepatic injury in both P. falciparum and P. vivax malaria, potentially integrating host immunogenetic profiles and parasite virulence factors to refine prognostic models and clinical care pathways in endemic settings. Acknowledgements We are thankful to the Vice Chancellor of Tehran University of Medical Sciences for the funding and support of the study. This work was supported by the Tehran University of Medical Sciences (Project No. 12-12-1404-91896). Footnotes Ethics considerations This study was approved by the ethics committee of Tehran University of Medical Sciences (IR.TUMS.SPH.REC.1404.276). Conflict of interest statement The authors have declared that no competing interests exist. References